Abstract
Alzheimer's disease (AD) is characterized by the accumulation of amyloid-β (Aβ) peptides. Although the disease undoubtedly reflects the interaction of complex multifactorial processes, Aβ itself is toxic to neurons in vitro and the load of Aβ in vivo correlates well with the degree of cognitive impairment. There has therefore been considerable interest in the mechanism(s) of Aβ neurotoxicity. We here review the basic biology of Aβ processing and consider some of the major areas of focus of this research. It is clear that both AD and Aβ toxicity are characterized by oxidative stress, alterations in the activity of enzymes of intermediary metabolism, and mitochondrial dysfunction, especially impaired activity of cytochrome c oxidase. Studies in vitro also show alterations in cellular calcium signaling. We consider the mechanisms proposed to mediate cell injury and explore evidence to indicate which of these many changes in function are primary and which secondary.
Similar content being viewed by others
References
Hardy, J., Duff, K., Hardy, K. G., Perez-Tur, J., and Hutton, M. 1998. Genetic dissection of Alzheimer's disease and related dementias: Amyloid and its relationship to tau. Nat. Neurosci. 1:355–358.
Lemere, C. A., Blusztajn, J. K., Yamaguchi, H., Wisniewski, T., Saido, T. C., and Selkoe, D. J. 1996. Sequence of deposition of heterogeneous amyloid β-peptides and APO E in Down syndrome: Implications for initial events in amyloid plaque formation. Neurobiol. Dis. 3:16–32.
Chapman, P. F., White, G. L., Jones, M. W., Cooper-Blacketer, D., Marshall, V. J., Irizarry, M., Younkin, L., Good, M. A., Bliss, T. V. P., Hyman, B. T., Younkin, S. G., and Hsiao, K. K. 1999. Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice. Nat. Neurosci. 2:271–276.
Phinney, A. L., Calhoun, M. E., Wolfer, D. P., Lipp, H. P., Zheng, H., and Jucker, M. 1999. No hippocampal neuron or synaptic bouton loss in learning-impaired aged beta-amyloid precursor protein-null mice. Neuroscience 90:1207–1216.
Snowdon, D. A. 1997. Aging and Alzheimer's disease: Lessons from the Nun study. Gerontologist 37:150–156.
Näslund, J., Haroutunian, V., Mohs, R., Davis, K.-L., Davies, P., Greengard, P., and Buxbaum, J.-D. 2000. Correlation between elevated levels of amyloid β-peptide in the brain and cognitive decline. JAMA 283:1571–1577.
Oddo, S., Caccamo, A., Shepherd, J. D., Murphy, M. P., Golde, T. E., Kayed, R., Metherate, R., Mattson, M. P., Akbari, Y., and LaFerla, F. M. 2003. Triple-transgenic model of Alzheimer's disease with plaques and tangles: Intracellular Abeta and synaptic dysfunction. Neuron 39:409–421.
Nishimoto, I., Okamoto, T., Matsuura, Y., Takahashi, S., Okamoto, T., Murayama, Y., and Ogata, E. 1993. Alzheimer amyloid protein precursor complexes with brain GTP-binding protein Go. Nature 362:75–79.
Kamal, A., Stokin, G. B., Yang, Z., Xia, C. H., and Goldstein, L. S. 2000. Axonal transport of amyloid precursor protein is mediated by direct binding to the kinesin light chain subunit of kinesin-I. Neuron 28:449–459.
Mattson, M. P. 1997. Cellular actions of β-amyloid precursor protein and its soluble and fibrillogenic derivatives. Physiol. Rev. 77:1081–1132.
Zheng, H., Jiang, M., Trumbauer, M. E., Sirinathsinghji, D. J., Hopkins, R., Smith, D. W., Heavens, R. P., Dawson, G. R., Boyce, S., and Conner, M. W. 1995. β-Amyloid precursor protein-deficient mice show reactive gliosis and decreased locomotor activity. Cell 81:525–531.
Kimberly, W. T., LaVoie, M. J., Ostaszewski, B. L., Ye, W., Wolfe, M. S., and Selkoe, D. J. 2003. γ-Secretase is a membrane protein complex comprised of presenilin, nicastrin, Aph-1, and Pen-2. Proc. Natl. Acad. Sci. USA 100:6382–6387.
Wolfe, M. S., De Los Angeles, J., Miller, D. D., Xia, W., and Selkoe, D. J. 1999. Are presenilins intramembrane-cleaving proteases? Implications for the molecular mechanism of Alzheimer's disease. Biochemistry 38:11223–11230.
Holsinger, R. M., McLean, C. A., Beyreuther, K., Masters, C. L., and Evin, G. 2002. Increased expression of the amyloid precursor β-secretase in Alzheimer's disease. Ann. Neurol. 51:783–786.
Roberds, S. L., Anderson, J., Basi, G., Bienkowski, M. J., Branstetter, D. G., Chen, K. S., Freedman, S. B., Frigon, N. L., Games, D., Hu, K., Johnson-Wood, K., Kappenman, K. E., Kawabe, T. T., Kola, I., Kuehn, R., Lee, M., Liu, W., Motter, R., Nichols, N. F., Power, M., Robertson, D. W., Schenk, D., Schoor, M., Shopp, G. M., Shuck, M. E., Sinha, S., Svensson, K. A., Tatsuno, G., Tintrup, H., Wijsman, J., Wright, S., and McConlogue, L. 2001. BACE knockout mice are healthy despite lacking the primary β-secretase activity in brain: Implications for Alzheimer's disease therapeutics. Hum. Mol. Genet. 10:1317–1324.
Tanzi, R. E., Kovacs, D. M., Kim, T. W., Moir, R. D., Guenette, S. Y., and Wasco, W. 1996. The gene defects responsible for familial Alzheimer's disease. Neurobiol. Dis. 3:159–168.
Cataldo, A. M., Peterhoff, C. M., Troncoso, J. C., Gomez-Isla, T., Hyman, B. T., and Nixon, R. A. 2000. Endocytic pathway abnormalities precede amyloid β deposition in sporadic Alzheimer's disease and Down syndrome: Differential effects of APOE genotype and presenilin mutations. Am. J. Pathol. 157:277–286.
Strittmatter, W. J., Saunders, A. M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G. S., and Roses, A. D. 1993. Apolipoprotein E: High-avidity binding to β-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc. Natl. Acad. Sci. USA 90:1977–1981.
Schmechel, D. E., Saunders, A. M., Strittmatter, W. J., Crain, B. J., Hulette, C. M., Joo, S. H., Pericak-Vance, M. A., Goldgaber, D., and Roses, A. D. 1993. Increased amyloid β-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc. Natl. Acad. Sci. USA 90: 9649–9653.
Yang, D. S., Smith, J. D., Zhou, Z., Gandy, S. E., and Martins, R. N. 1997. Characterization of the binding of amyloid-β peptide to cell culture-derived native apolipoprotein E2, E3, and E4 isoforms and to isoforms from human plasma. J. Neurochem. 68:721–725.
Puttfarcken, P. S., Manelli, A. M., Falduto, M. T., Getz, G. S., and LaDu, M. J. 1997. Effect of apolipoprotein E on neurite outgrowth and β-amyloid-induced toxicity in developing rat primary hippocampal cultures. J. Neurochem. 68:760–769.
Pike, C. J., Burdick, D., Walencewicz, A. J., Glabe, C. G., and Cotman, C. W. 1993. Neurodegeneration induced by β-amyloid peptides in vitro: The role of peptide assembly state. J. Neurosci. 13:1676–1687.
Geula, C., Wu, C. K., Saroff, D., Lorenzo, A., Yuan, M., and Yankner, B. A. 1998. Aging renders the brain vulnerable to amyloid β-protein neurotoxicity. Nat. Med. 4:827–831.
Snyder, S. W., Ladror, U. S., Wade, W. S., Wang, G. T., Barrett, L. W., Matayoshi, E. D., Huffaker, H. J., Krafft, G. A., and Holzman, T. F. 1994. Amyloid-β aggregation: selective inhibition of aggregation in mixtures of amyloid with different chain lengths. Biophys. J. 67:1216–1228.
Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., Morgan, T. F., Rozovsky, I., Trommer, B., Viola, K. L., Wals, P., Zhang, C., Finch, C. E., Krafft, G. A., and Klein, W. L. 1998. Diffusible, nonfibrillar ligands derived from A β1–42 are potent central nervous system neurotoxins. Proc. Natl. Acad. Sci. USA 95:6448–6453.
Walsh, D. M., Hartley, D. M., Kusumoto, Y., Fezoui, Y., Condron, M. M., Lomakin, A., Benedek, G. B., Selkoe, D. J., and Teplow, D. B. 1999. Amyloid β-protein fibrillogenesis: Structure and biological activity of protofibrillar intermediates. J. Biol. Chem. 274:25945–25952.
Klein, W. L., Krafft, G. A., and Finch, C. E. 2001. Targeting small Aβ oligomers: The solution to an Alzheimer's disease conundrum? Trends Neurosci. 24:219–224.
Burdick, D., Soreghan, B., Kwon, M., Kosmoski, J., Knauer, M., Henschen, A., Yates, J., Cotman, C., and Glabe, C. 1992. Assembly and aggregation properties of synthetic Alzheimer's A4/β amyloid peptide analogs. J. Biol. Chem. 267:546–554.
Mantyh, P. W., Ghilardi, J. R., Rogers, S., DeMaster, E., Allen, C. J., Stimson, E. R., and Maggio, J. E. 1993. Aluminum, iron, and zinc ions promote aggregation of physiological concentrations of β-amyloid peptide. J. Neurochem. 61:1171–1174.
Klunk, W. E., Xu, C. J., McClure, R. J., Panchalingam, K., Stanley, J. A., and Pettegrew, J. W. 1997. Aggregation of β-amyloid peptide is promoted by membrane phospholipid metabolites elevated in Alzheimer's disease brain. J. Neurochem. 69: 266–272.
Dyrks, T., Dyrks, E., Hartmann, T., Masters, C., and Beyreuther, K. 1992. Amyloidogenicity of βA4 and βA4-bearing amyloid protein precursor fragments by metal-catalyzed oxidation. J. Biol. Chem. 267:18210–18217.
Walsh, D. M., Tseng, B. P., Rydel, R. E., Podlisny, M. B., and Selkoe, D. J. 2000. The oligomerization of amyloid β-protein begins intracellularly in cells derived from human brain. Biochemistry 39:10831–10839.
D'Andrea, M. R., Nagele, R. G., Wang, H. Y., Peterson, P. A., and Lee, D. H. 2001. Evidence that neurones accumulating amyloid can undergo lysis to form amyloid plaques in Alzheimer's disease. Histopathology 38:120–134.
Meyer-Luehmann, M., Stalder, M., Herzig, M. C., Kaeser, S. A., Kohler, E., Pfeifer, M. D., Boncristiano, S., Mathews, P. M., Mercken, M., Abramowski, D., Staufenbiel, M., and Jucker, M. 2003. Extracellular amyloid formation and associated pathology in neural grafts. Nat. Neurosci. 6:370–377.
Grundke-Iqbal, I., Iqbal, K., George, L., Tung, Y. C., Kim, K. S., and Wisniewski, H. M. 1989. Amyloid protein and neurofibrillary tangles coexist in the same neuron in Alzheimer disease. Proc. Natl. Acad. Sci. USA 86:2853–2857.
Ginsberg, S. D., Crino, P. B., Hemby, S. E., Weingarten, J. A., Lee, V. M., Eberwine, J., and Trojanowski, J. Q. 1999. Predominance of neuronal mRNAs in individual Alzheimer's disease senile plaques. Ann. Neurol. 45:174–181.
Li, Q. X., Maynard, C., Cappai, R., McLean, C. A., Cherny, R. A., Lynch, T., Culvenor, J. G., Trevaskis, J., Tanner, J. E., Bailey, K. A., Czech, C., Bush, A., Beyreuther, K., and Masters, C. L. 1999. Intracellular accumulation of detergent-soluble amyloidogenic Aβ fragment of Alzheimer's disease precursor protein in the hippocampus of aged transgenic mice. J. Neurochem. 72:2479–2487.
Gouras, G. K., Tsai, J., Näslund, J., Vincent, B., Edgar, M., Checler, F., Greenfield, J. P., Haroutunian, V., Buxbaum, J. D., Xu, H., Greengard, P., and Relkin, N. R. 2000. Intraneuronal Aβ42 accumulation in human brain. Am. J. Pathol. 156:15–20.
Takahashi, R. H., Milner, T. A., Li, F., Nam, E. E., Edgar, M. A., Yamaguchi, H., Beal, M. F., Xu, H., Greengard, P., and Gouras, G. K. 2002. Intraneuronal Alzheimer Aβ42 accumulates in multivesicular bodies and is associated with synaptic pathology. Am. J. Pathol. 161:1869–1879.
Oddo, S., Caccamo, A., Shepherd, J. D., Murphy, M. P., Golde, T. E., Kayed, Metherate, R., Mattson, M. P., Akbari, Y., and LaFerla, F. M. 2003. Triple-transgenic model of Alzheimer's disease with plaques and tangles: Intracellular Aβ and synaptic dysfunction. Neuron 39:409–421.
Maruyama, K., Tagawa, K., Kawamura, Y., Asada, H., Ishiura, S., and Obata, K. 1995. Secretion of Alzheimer βA4 protein (1–40) and intracellular retention of βA4 protein (1–42) in transfected COS cells. Biochem. Biophys. Res. Comm. 207:971–917.
Turner, R. S., Suzuki, N., Chyung, A. S., Younkin, S. G., and Lee, V. M. 1996. Amyloids β40 and β42 are generated intracellularly in cultured human neurons and their secretion increases with maturation. J. Biol. Chem. 271:8966–8970.
Wild-Bode, C., Yamazaki, T., Capell, A., Leimer, U., Steiner, H., Ihara, Y., and Haass, C. 1997. Intracellular generation and accumulation of amyloid β-peptide terminating at amino acid 42. J. Biol. Chem. 272:16085–16088.
Tienari, P. J., Ida, N., Ikonen, E., Simons, M., Weidemann, A., Multhaup, G., Masters, C. L., Dotti, C. G., and Beyreuther, K. 1997. Intracellular and secreted Alzheimer β-amyloid species are generated by distinct mechanisms in cultured hippocampal neurons. Proc. Natl. Acad. Sci. USA 94:4125–4130.
Greenfield, J. P., Tsai, J., Gouras, G. K., Hai, B., Thinakaran, G., Checler, F., Sisodia, S. S., Greengard, P., and Xu, H. 1999. Endoplasmic reticulum and trans-Golgi network generate distinct populations of Alzheimer β-amyloid peptides. Proc. Natl. Acad. Sci. USA 96:742–747.
Wilson, C. A., Doms, R. W., and Lee, V. M. 1999. Intracellular APP processing and Aβ production in Alzheimer disease. J. Neuropathol. Exp. Neurol. 58:787–794.
Lucassen, P. J., Chung, W. C., Kamphorst, W., and Swaab, D. F. 1997. DNA damage distribution in the human brain as shown by in situ end labeling: Area-specific differences in aging and Alzheimer disease in the absence of apoptotic morphology. J. Neuropathol. Exp. Neurol. 56:887–900.
Guo, Q., Fu, W., Sopher, B. L., Miller, M. W., Ware, C. B., Martin, G. M., and Mattson, M. P. 1999. Increased vulnerability of hippocampal neurons to excitotoxic necrosis in presenilin-1 mutant knock-in mice. Nat. Med. 5:101–106.
Behl, C., Davis, J. B., Klier, F. G., and Schubert, D. 1994. Amyloid β peptide induces necrosis rather than apoptosis. Brain Res. 645:253–264.
Su, J. H., Anderson, A. J., Cummings, B. J., and Cotman, C. W. 1994. Immunohistochemical evidence for apoptosis in Alzheimer's disease. Neuroreport 5:2529–2533.
Kitamura, Y., Shimohama, S., Kamoshima, W., Ota, T., Matsuoka, Y., Nomura, Y., Smith, M. A., Perry, G., Whitehouse, P. J., and Taniguchi, T. 1998. Alteration of proteins regulating apoptosis, Bcl-2, Bcl-x, Bax, Bak, Bad, ICH-1 and CPP32, in Alzheimer's disease. Brain Res. 780:260–269.
Engidawork, E., Gulesserian, T., Seidl, R., Cairns, N., and Lubec, G. 2001. Expression of apoptosis related proteins in brains of patients with Alzheimer's disease. Neurosci. Lett. 303:79–82.
Yang, F., Sun, X., Beech, W., Teter, B., Wu, S., Sigel, J., Vinters, H. V., Frautschy, S. A., and Cole, G. M. 1998. Antibody to caspase-cleaved actin detects apoptosis in differentiated neuroblastoma and plaque-associated neurons and microglia in Alzheimer's disease. Am. J. Pathol. 152:379–389.
Estus, S., Tucker, H. M., van Rooyen, C., Wright, S., Brigham, E. F., Wogulis, M., and Rydel, R. E. 1997. Aggregated amyloid-β protein induces cortical neuronal apoptosis and concomitant “apoptotic” pattern of gene induction. J. Neurosci. 17:7736–7745.
Kienlen-Campard, P., Miolet, S., Tasiaux, B., and Octave, J. N. 2002. Intracellular amyloid-β 1–42, but not extracellular soluble amyloid-β peptides, induces neuronal apoptosis. J. Biol. Chem. 277:15666–15670.
Tamagno, E., Parola, M., Guglielmotto, M., Santoro, G., Bardini, P., Marra, L., Tabaton, M., and Danni, Q. 2003. Multiple signaling events in amyloid β-induced, oxidative stress-dependent neuronal apoptosis. Free Rad. Biol. Med. 35:45–58.
Roth, K. A. 2001. Caspases, apoptosis, and Alzheimer disease: Causation, correlation, and confusion. J. Neuropathol. Exp. Neurol. 60:829–838.
Kim., T. W., Pettingell, W. H., Jung, Y. K., Kovacs, D. M., and Tanzi, R. E. 1997. Alternative cleavage of Alzheimer-associated presenilins during apoptosis by a caspase-3 family protease. Science 277:373–376.
Gervais, F. G., Xu, D., Robertson, G. S., Vaillancourt, J. P., Zhu, Y., Huang, J., LeBlanc, A., Smith, D., Rigby, M., Shearman, M. S., Clarke, E. E., Zheng, H., Van Der Ploeg, L. H., Ruffolo, S. C., Thornberry, N. A., Xanthoudakis, S., Zamboni, R. J., Roy, S., and Nicholson, D. W. 1999. Involvement of caspases in proteolytic cleavage of Alzheimer's amyloid-β precursor protein and amyloidogenic Aβ peptide formation. Cell 97:395–406.
Regeur, L., Jensen, G. B., Pakkenberg, H., Evans, S. M., and Pakkenberg, B. 1994. No global neocortical nerve cell loss in brains from patients with senile dementia of Alzheimer's type. Neurobiol. Aging 15:347–352.
Ibanez. V., Pietrini, P., Alexander, G. E., Furey, M. L., Teichberg, D., Rajapakse, J. C., Rapoport, S. I., Schapiro, M. B., and Horwitz, B. 1998. Regional glucose metabolic abnormalities are not the result of atrophy in Alzheimer's disease. Neurology 50:1585–1593.
de la Monte, S. M., Luong, T., Neely, T. R., Robinson, D., and Wands, J. R. 2000. Mitochondrial DNA damage as a mechanism of cell loss in Alzheimer's disease. Lab. Invest. 80:1323–1335.
Hirai, K., Aliev, G., Nunomura, A., Fujioka, H., Russell, R. L., Atwood, C. S., Johnson, A. B., Kress, Y., Vinters, H. V., Tabaton, M., Shimohama, S., Cash, A. D., Siedlak, S. L., Harris, P. L., Jones, P. K., Peterson, R. B., Perry, G., and Smith, M. A. 2001. Mitochondrial abnormalities in Alzheimer's disease. J. Neurosci. 21:3017–3023.
Anandatheerthavarada, H. K., Biswas, G., Robin, M. A., and Avadhani, N. G. 2003. Mitochondrial targeting and a novel transmembrane arrest of Alzheimer's amyloid precursor protein impairs mitochondrial function in neuronal cells. J. Cell Biol. 161:41–54.
Khan, S. M., Cassarino, D. S., Abramova, N. N., Keeney, P. M., Borland, M. K., Trimmer, P. A., Krebs, C. T., Bennett, J. C., Parks, J. K., Swerdlow, R. H., Parker, W. D. Jr., and Bennett, J. P. Jr. 2000. Alzheimer's disease cybrids replicate β-amyloid abnormalities through cell death pathways. Ann. Neurol. 48:148–155.
Trimmer, P. A., Swerdlow, R. H., Parks, J. K., Keeney, P., Bennett, J. P. Jr., Miller, S. W., Davis, R. E., and Parker, W. D. Jr., 2000. Abnormal mitochondrial morphology in sporadic Parkinson's and Alzheimer's disease cybrid cell lines. Exp. Neurol. 162:37–50.
Lin, M. T., Simon, D. K., Ahn, C. H., Kim, L. M., and Beal, M. F. 2002. High aggregate burden of somatic mtDNA point mutations in aging and Alzheimer's disease brain. Hum. Mol. Genet. 11:133–145.
Gibson, G. E., Zhang, H., Sheu, K. F., Bogdanovich, N., Lindsay, J. G., Lannfelt, L., Vestling, M., and Cowburn, R. F. 1998. ά-Ketoglutarate dehydrogenase in Alzheimer brains bearing the APP670/671 mutation. Ann. Neurol. 44:676–681.
Sheu, K. F., Kim, Y. T., Blass, J. P., and Weksler, M. E. 1985. An immunochemical study of the pyruvate dehydrogenase deficit in Alzheimer's disease brain. Ann. Neurol. 17:444–449.
Kish, S. J., Bergeron, C., Rajput, A., Dozic, S., Mastrogiacomo, F., Chang, L. J., Wilson, J. M., DiStefano, L. M., and Nobrega, J. N. 1992. Brain cytochrome oxidase in Alzheimer's disease. J. Neurochem. 59:776–779.
Mutisya, E. M., Bowling, A. C., and Beal, M. F. 1994. Cortical cytochrome oxidase activity is reduced in Alzheimer's disease. J. Neurochem. 63:2179–2184.
Chandrasekaran, K., Hatanpaa, K., Brady, D. R., and Rapoport, S. I. 1996. Evidence for physiological down-regulation of brain oxidative phosphorylation in Alzheimer's disease. Exp. Neurol. 142:80–88.
Bedetti, C. D. 1985. Immunocytochemical demonstration of cytochrome c oxidase with an immunoperoxidase method: A specific stain for mitochondria in formalin-fixed and paraffin-embedded human tissues. J. Histochem. Cytochem. 33:446–452.
Parker, W. D. Jr., Mahr, N. J., Filley, C. M., Parks, J. K., Hughes, D., Young, D. A., and Cullum, C. M. 1994. Reduced platelet cytochrome c oxidase activity in Alzheimer's disease. Neurology. 44:1086–1090.
Askanas, V., McFerrin, J., Baqué, S., Alvarez, R. B., Sarkozi, E., and Engel, W. K. 1996. Transfer of β-amyloid precursor protein gene using adenovirus vector causes mitochondrial abnormalities in cultured normal human muscle. Proc. Natl. Acad. Sci. USA 93:1314–1319.
Grant, S. M., Shankar, S. L., Chalmers-Redman, R. M., Tatton, W. G., Szyf, M., and Cuello, A. C. 1999. Mitochondrial abnormalities in neuroectodermal cells stably expressing human amyloid precursor protein (hAPP751). Neuroreport 10:41–46.
Pereira, C., Santos, M. S., and Oliveira, C. 1998. Mitochondrial function impairment induced by amyloid β-peptide on PC12 cells.Neuroreport 9:1749–1755.
Canevari, L., Clark, J. B., and Bates, T. E. 1999. β-Amyloid fragment 25–35 selectively decreases complex IV activity in isolated mitochondria. FEBS Lett. 457:131–134.
Casley, C. S., Canevari, L., Land, J. M., Clark, J. B., and Sharpe, M. A. 2002. β-Amyloid inhibits integrated mitochondrial respiration and key enzyme activities. J. Neurochem. 80:91–100.
Cardoso, S. M., Santos, S., Swerdlow, R. H., and Oliveira, C. R. 2001. Functional mitochondria are required for amyloid β-mediated neurotoxicity. FASEB J. 15:1439–1441.
Shevtzova, E. F., Kireeva, E. G., and Bachurin, S. O. 2001. Effect of β-amyloid peptide fragment 25–35 on nonselective permeability of mitochondria. Bull. Exp. Biol. Med. 132:1173–1176.
Cadenas, E., Boveris, A., Ragan, C. I., and Stoppani, A. O. M. 1977. Production of superoxide radicals and hydrogen peroxide by NADH-ubiquinone reductase and ubiquinol-cytochrome c reductase from beef-heart mitochondria. Arch. Biochem. Biophys. 180: 248–257.
Gabuzda, D., Busciglio, J., Chen, L. B., Matsudaira, P., and Yankner, B. A. 1994. Inhibition of energy metabolism alters the processing of amyloid precursor protein and induces a potentially amyloidogenic derivative. J. Biol. Chem. 269: 13623–13628.
Smith, M. A., Richey Harris, P. L., Sayre, L. M., Beckman, J. S., and Perry, G. 1997. Widespread peroxynitrite-mediated damage in Alzheimer's disease. J. Neurosci. 17:2653–2657.
Varadarajan, S., Yatin, S., Aksenova, M., and Butterfield, D. A. 2000. Alzheimer's amyloid β-peptide-associated free radical oxidative stress and neurotoxicity. J. Struct. Biol. 30:184–208.
Kish, S. J. 1997. Brain energy metabolizing enzymes in Alzheimer's disease: ά-Ketoglutarate dehydrogenase complex and cytochrome oxidase: Ann. NY Acad. Sci., 826:218–228.
Gibson, G. E., Park, L. C., Sheu, K. F., Blass, J. P., and Calingasan, N. Y. 2000. The ά-ketoglutarate dehydrogenase complex in neurodegeneration. Neurochem. Int. 36:97–112.
Tretter, L., and Adam-Vizi, V. 2000. Inhibition of Krebs cycle enzymes by hydrogen peroxide: A key role of ά-ketoglutarate dehydrogenase in limiting NADH production under oxidative stress. J. Neurosci. 20:8972–8979.
Harris, M. E., Wang, Y., Pedigo, N. W. Jr., Hensley, K., Butterfield, D. A., and Carney, J. M. 1996. Amyloid β peptide (25–35) inhibits Na+-dependent glutamate uptake in rat hippocampal astrocyte cultures. J Neurochem. 67:277–286.
Abe, K. and Misawa, M. 2003. Amyloid β protein enhances the clearance of extracellular L-glutamate by cultured rat cortical astrocytes. Neurosci. Res. 45:25–31.
Cecchi, C., Latorraca, S., Sorbi, S., lantomasi, T., Favilli, F., Vincenzini, M. T., and Liguri, G. 1999. Gluthatione level is altered in lymphoblasts from patients with familial Alzheimer's disease. Neurosci. Lett. 275:152–154.
Muller, W. E., Romero, F. J., Perovic, S., Pergande, G., and Pialoglou, P. 1997. Protection of flupirtine on β-amyloid-induced apoptosis in neuronal cells in vitro: Prevention of amyloid-induced glutathione depletion. J. Neurochem. 68:71–77.
Abramov, A. Y., Canevari, L., and Duchen, M. R. 2003. Changes in intracellular calcium and glutathione in astrocytes as the primary mechanism of amyloid neurotoxicity. J. Neurosci. 23:5088–5095.
Keelan, J., Allen, N. J., Antcliffe, D., Pal, S., and Duchen, M. R. 2001. Quantitative imaging of glutathione in hippocampal neurons and glia in culture using monochlorobimane. J. Neurosci. Res. 66:873–884.
Dringen, R. and Hirrlinger, J. 2003. Glutathione pathways in the brain. Biol. Chem. 384:505–516.
Barkats, M., Millecamps, S., Abrioux, P., Geoffroy, M. C., and Mallet, J. 2000. Overexpression of glutathione peroxidase increases the resistance of neuronal cells to Aβ-mediated neurotoxicity. J. Neurochem. 75:1438–1446.
Benzi, G. and Moretti, A. 1995. Are reactive oxygen species involved in Alzheimer's disease? Neurobiol. Aging 16:661–674.
Atwood, C. S., Moir, R. D., Huang, X., Scarpa, R. C., Bacarra, N. M., Romano, D. M., Hartshorn, M. A., Tanzi, R. E., and Bush, A. I. 1998. Dramatic aggregation of Alzheimer Aβ by Cu(II) is induced by conditions representing physiological acidosis. J. Biol. Chem. 273:12817–12826.
Cuajungco, M. P., Goldstein, L. E., Nunomura, A., Smith, M. A., Lim, J. T., Atwood, C. S., Huang, X., Farrag, Y. W., Perry, G., and Bush, A. I. 2000. Evidence that the β-amyloid plaques of Alzheimer's disease represent the redox-silencing and entombment of Aβ by zinc. J. Biol. Chem. 275:19439–19442.
Cherny, R. A., Atwood, C. S., Xilinas, M. E., Gray, D. N., Jones, W. D., McLean, C. A., Barnham, K. J., Volitakis, I., Fraser, F. W., Kim, Y., Huang, X., Goldstein, L. E., Moir, R. D., Lim, J. I., Beyreuther, K., Zheng, H., Tanzi, R. E., Masters, C. L., and Bush, A. I. 2001. Treatment with a copper-zinc chelator markedly and rapidly inhibits β-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 30:665–676.
Melov, S. 2002. ' ... and C is for Clioquinol': The AβCs of Alzheimer's disease. Trends Neurosci. 25:121–123.
Sheehan, J. P., Swerdlow, R. H., Miller, S. W., Davis, R. E., Parks, J. K., Parker, W. D., and Tuttle, J. B. 1997. Calcium homeostasis and reactive oxygen species production in cells transformed by mitochondria from individuals with sporadic Alzheimer's disease. J. Neurosci. 17:4612–4622.
Meda, L., Bonaiuto, C., Baron, P., Otvos, L. Jr., Rossi, F., and Cassatella, M. A. 1996. Priming of monocyte respiratory burst by β-amyloid fragment (25–35). Neurosci. Lett. 219:91–94.
Parvathenani, L. K., Tertyshnikova, S., Greco, C. R., Roberts, S. B., Robertson, B., and Posmantur, R. 2003. P2X7 mediates superoxide production in primary microglia and is up-regulated in a transgenic mouse model of Alzheimer's disease. J. Biol. Chem. 278:13309–13317.
Husemann, J. and Silverstein, S. C. 2001. Expression of scavenger receptor class B, type I, by astrocytes and vascular smooth muscle cells in normal adult mouse and human brain and in Alzheimer's disease brain. Am. J. Pathol. 158:825–832.
El Khoury, J. B., Moore, K. J., Means, T. K., Leung, J., Terada, K., Toft, M., Freeman, M. W., and Luster, A. D. 2003. CD36 mediates the innate host response to β-amyloid. J. Exp. Med. 197:1657–1666.
Wautier, M. P., Chappey, O., Corda, S., Stern, D. M., Schmidt, A. M., and Wautier, J. L. 2001. Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am. J. Physiol. Endocrinol. Metab. 280:E685–694.
Yan, S. D., Chen, X., Fu, J., Chen, M., Zhu, H., Roher, A., Slattery, T., Zhao, L., Nagashima, M., Morser, J., Migheli, A., Nawroth, P., Stern, D., and Schmidt, A. M. 1996. RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease. Nature 382:685–691.
Lee, M., You, H. J., Cho, S. H., Woo, C. H., Yoo, M. H., Joe, E. H., and Kim, J. H. 2002. Implication of the small GTPase Rac1 in the generation of reactive oxygen species in response to β-amyloid in C6 astroglioma cells. Biochem. J. 366:937–943.
Pocock, J. M. and Liddle, A. C. 2001. Microglial signalling cascades in neurodegenerative disease. Prog. Brain Res. 132:555–565.
Ho, R., Ortiz, D., and Shea, T. B. 2001. Amyloid-β promotes calcium influx and neurodegeneration via stimulation of L voltage-sensitive calcium channels rather than NMDA channels in cultured neurons. J. Alzheimers Dis. 3:479–483.
Rovira, C., Arbez, N., and Mariani, J. 2002. Aβ(25–35) and Aβ(1–40) act on different calcium channels in CA1 hippocampal neurons. Biochem. Biophys. Res. Commun. 296:1317–1321.
Green, K. N. and Peers, C. 2001. Amyloid β peptides mediate hypoxic augmentation of Ca2+ channels. J. Neurochem. 77:953–956.
Kasparova, J., Lisa, V., Tuček, S., and Dolezal, V. 2001. Chronic exposure of NG108-15 cells to amyloid β peptide (Aβ1–42) abolishes calcium influx via N-type calcium channels. Neurochem. Res. 26:1079–1084.
Huang, H. M., Ou, H. C., and Hsieh, S. J. 2000. Antioxidants prevent amyloid peptide-induced apoptosis and alteration of calcium homeostasis in cultured cortical neurons. Life Sci. 66:1879–1892.
Kelly, J. F., Furukawa, K., Barger, S. W., Rengen, M. R., Mark, R. J., Blanc, E. M., Roth, G. S., and Mattson, M. P. 1996. Amyloid β-peptide disrupts carbachol-induced muscarinic cholinergic signal transduction in cortical neurons. Proc. Natl. Acad. Sci. USA 93:6753–6758.
Pike, C. J., Balazs, R., and Cotman, C. W. 1996. Attenuation of β-amyloid neurotoxicity in vitro by potassium-induced depolarization. J. Neurochem. 67:1774–1777.
Blanchard, B. J., Konopka, G., Russell, M., and Ingram, V. M. 1997. Mechanism and prevention of neurotoxicity caused by β-amyloid peptides: Relation to Alzheimer's disease. Brain Res. 776:40–50.
Arispe, N., Pollard, H. B., and Rojas, E. 1993. Giant multilevel cation channels formed by Alzheimer disease amyloid β-protein [AβP-(1–40)] in bilayer membranes. Proc. Natl. Acad. Sci. USA 90:10573–10577.
Rhee, S. K., Quist, A. P., and Lal, R. 1998. Amyloid β protein-(1–42) forms calcium-permeable, Zn2+-sensitive channel. J. Biol. Chem. 273:13379–13382.
Arispe, N., Pollard, H. B., and Rojas, E. 1996. Zn2+ interaction with Alzheimer amyloid β protein calcium channels. Proc. Natl. Acad. Sci. USA 93:1710–1715.
Bush, A. J. 2003. The metallobiology of Alzheimer's disease. Trends Neurosci. 26:207–214.
Lin, H., Bhatia, R., and Lal, R. 2001. Amyloid β protein forms ion channels: Implications for Alzheimer's disease pathophysiology. FASEB J. 15:2433–2444.
Bhatia, R., Lin, H., and Lal, R. 2000. Fresh and globular amyloid β protein (1–42) induces rapid cellular degeneration: Evidence for AβP channel-mediated cellular toxicity. FASEB J. 14:1233–1243.
Arispe, N. and Doh, M. 2002. Plasma membrane cholesterol controls the cytotoxicity of Alzheimer's disease AβP (1–40) and (1–42) peptides FASEB J. 16:1526–1536.
Kawahara, M. and Kuroda, Y. 2001. Intracellular calcium changes in neuronal cells induced by Alzheimer's β-amyloid protein are blocked by estradiol and cholesterol. Cell. Mol. Neurobiol. 21:1–13.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Canevari, L., Abramov, A.Y. & Duchen, M.R. Toxicity of Amyloid β Peptide: Tales of Calcium, Mitochondria, and Oxidative Stress. Neurochem Res 29, 637–650 (2004). https://doi.org/10.1023/B:NERE.0000014834.06405.af
Issue Date:
DOI: https://doi.org/10.1023/B:NERE.0000014834.06405.af